Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1016/j.str.2020.10.007

http://scihub22266oqcxt.onion/10.1016/j.str.2020.10.007
suck pdf from google scholar
33152262!7584437!33152262
unlimited free pdf from europmc33152262    free
PDF from PMC    free
html from PMC    free
PDF vom PMID33152262  :  Publisher

suck abstract from ncbi

pmid33152262
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Malleability of the SARS-CoV-2 3CL M(pro) Active-Site Cavity Facilitates Binding of Clinical Antivirals #MMPMID33152262
  • Kneller DW; Galanie S; Phillips G; O'Neill HM; Coates L; Kovalevsky A
  • Structure 2020[Dec]; 28 (12): 1313-1320.e3 PMID33152262show ga
  • The COVID-19 pandemic caused by SARS-CoV-2 requires rapid development of specific therapeutics and vaccines. The main protease of SARS-CoV-2, 3CL M(pro), is an established drug target for the design of inhibitors to stop the virus replication. Repurposing existing clinical drugs can offer a faster route to treatments. Here, we report on the binding mode and inhibition properties of several inhibitors using room temperature X-ray crystallography and in vitro enzyme kinetics. The enzyme active-site cavity reveals a high degree of malleability, allowing aldehyde leupeptin and hepatitis C clinical protease inhibitors (telaprevir, narlaprevir, and boceprevir) to bind and inhibit SARS-CoV-2 3CL M(pro). Narlaprevir, boceprevir, and telaprevir are low-micromolar inhibitors, whereas the binding affinity of leupeptin is substantially weaker. Repurposing hepatitis C clinical drugs as COVID-19 treatments may be a useful option to pursue. The observed malleability of the enzyme active-site cavity should be considered for the successful design of specific protease inhibitors.
  • |*Antiviral Agents/pharmacology[MESH]
  • |*Betacoronavirus/metabolism[MESH]
  • |*COVID-19[MESH]
  • |*Coronavirus Infections/drug therapy[MESH]
  • |Catalytic Domain[MESH]
  • |Crystallography, X-Ray[MESH]
  • |Cysteine Endopeptidases/metabolism[MESH]
  • |Humans[MESH]
  • |Pandemics[MESH]
  • |Protease Inhibitors/pharmacology[MESH]
  • |SARS-CoV-2[MESH]
  • |Temperature[MESH]
  • |Viral Nonstructural Proteins[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    1313 12.28 2020